BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target

BTIG reiterated their Buy rating on Aldeyra Therapeutics's stock with a price target of $9.00.The price target implies an upside of 675.9% from the Sep 28 close of $1.16.Key takeaways from the analyst notePositive Trial Results: Aldeyra Therapeutics has demonstrated a significant number of positive…